Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
FDA considered the planned HER-096 Phase 2a study design appropriateStudy design finalized; approximately 100 patients to be enrolledMore than 50% of Phase 2 funding secured or identified Espoo,...
-
FDA considered the planned HER-096 Phase 2a study design appropriateStudy design finalized; approximately 100 patients to be enrolledMore than 50% of Phase 2 funding secured or identified Espoo,...
-
Herantis Pharma Plc – Press release Indivi’s digital biomarker platform is designed to enable earlier and more sensitive detection of treatment-related changes Improved sensitivity and reduced...
-
Funding to support the execution of a Phase 2 proof-of-concept trial of HER-096 in Parkinson’s disease, following completion of study preparations Espoo, Finland, 19 February 2026: Herantis Pharma...